Role of savolitinib in advanced gastric adenocarcinoma with meningeal carcinomatosis and cerebellar metastasis:A case report  

作　　者：Zhi-Yun Weng Wen-Ye Huang Bin-Kan Shi Jian-Jia Pan 

机构地区：[1]Department of Hematology,The Affiliated Yueqing Hospital of Wenzhou Medical University,Yueqing 325600,Zhejiang Province,China

出　　处：《World Journal of Clinical Cases》2024年第15期2636-2641,共6页世界临床病例杂志

摘　　要：BACKGROUND Brain metastases(BM)are very rare in gastric adenocarcinoma(GaC),and patients with BMs have a higher mortality rate due to stronger tumor aggressiveness.However,its pathogenesis remains unclear.Genetic testing revealed cellular-mesenchymal epithelial transition factor receptor(MET)amplification.Therefore,treatment with savolitinib,a small molecule inhibitor of c-Met,was selected.CASE SUMMARY A 66-year-old woman was diagnosed with advanced GaC 6 months prior to presentation due to back pain.Cerebellar and meningeal metastases were observed during candonilimab combined with oxaliplatin and capecitabine therapy.The patient experienced frequent generalized seizures and persistent drowsiness in the emergency department.Genetic testing of cerebrospinal fluid and peripheral blood revealed increased MET amplification.After discussing treatment options with the patient,savolitinib tablets were administered.After a month of treatment,the intracranial lesions shrank considerably.CONCLUSION BM is very rare in advanced GaC,especially in meningeal cancer,that is characterized by rapid disease deterioration.There are very few effective treatment options available;however,technological breakthroughs in genomics have provided a basis for personalized treatment.Furthermore,MET amplification may be a key driver of BM in gastric cancer;however,this conclusion requires further investigation.

关 键 词：Cellular-mesenchymal epithelial transition factor receptor Savolitinib Meningeal carcinomatosis Gastric adenocarcinoma Case report 

分 类 号：R734.2[医药卫生—肿瘤]